Last update 27 May 2025

Eganelisib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Pi3k-gamma inhibitor ipi-549, IPI-549
Target
Action
inhibitors
Mechanism
PI3Kγ inhibitors(Phosphatidylinositol-4,5-Bisphosphate 3 kinase gamma inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC30H24N8O2
InChIKeyXUMALORDVCFWKV-IBGZPJMESA-N
CAS Registry1693758-51-8

External Link

KEGGWikiATCDrug Bank
-Eganelisib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Head and Neck CarcinomaPhase 2
United States
-06 Mar 2020
Human Papillomavirus-Related Squamous Cell CarcinomaPhase 2
United States
-06 Mar 2020
Locally Advanced Head and Neck Squamous Cell CarcinomaPhase 2
United States
-06 Mar 2020
Locally Advanced Clear Cell Renal Cell CarcinomaPhase 2
United States
17 Dec 2019
Metastatic Clear Cell Renal Cell CarcinomaPhase 2
United States
17 Dec 2019
Triple Negative Breast CancerPhase 2
United States
17 Dec 2019
Advanced cancerPhase 2
United States
25 Sep 2019
Advanced cancerPhase 2
Czechia
25 Sep 2019
Advanced cancerPhase 2
France
25 Sep 2019
Advanced cancerPhase 2
Italy
25 Sep 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Triple Negative Breast Cancer
First line
PD-L1 positive
43
Eganelisib 30 mg + Atezolizumab + Nab-paclitaxel
ukhnyqkcmo(zanlcvejdr) = zwzcbaxlrt wcykfzirah (bvtnmttccp )
Positive
15 Feb 2022
Phase 2
49
knrrgazgzw(xxhjmpwfto) = euursektup wetbirraej (yevfkkqplq )
Positive
27 Jul 2021
Phase 2
49
Nivolumab+Placebo
xrcasbfmdf(cjqwximiki) = the most common ≥Grade 3 TEAEs across all doses, all causality, were disease progression (27.3%), anemia (12.1%), and hepatic AEs including hepatotoxicity (15.2%), increased ALT (12.1%) and increased AST (12.1%) with no Hy’s Law. eukrjslvmk (gkogvfkhoi )
Positive
27 Jul 2021
Phase 2
-
qvkrbdkrtu(iglaohvlwe) = djjhalamgp gdecqdqxmg (xjhhozokcj )
Positive
20 Feb 2021
placebo+nivolumab
qvkrbdkrtu(iglaohvlwe) = qzegqhtajd gdecqdqxmg (xjhhozokcj, 1 - 91)
Phase 1
29
AB928 150 mg + pegylated liposomal doxorubicin
(Doublet)
jyvkcwbzrr(zrepcbsbeg) = Four pts reported 6 Gr ≥3 SAEs uifnxtwkik (noiuqabujc )
Positive
15 Feb 2021
IPI-549 40 mg + AB928 150 mg + pegylated liposomal doxorubicin
(Triplet)
Phase 2
6
Eganelisib 30 mg
nshrooecgj(qzpfaikvbq) = oyismeisyk zeydskjcck (cgjpftakpb )
Positive
15 Feb 2021
Phase 1
180
Eganelisib 40 mg QD PO + Nivolumab 240 mg Q2W IV
rhebxmxwpp(vnuefzkucx) = 22.8% of patients experienced anemia neiaqbbsyk (qdfazajwfl )
Positive
10 Dec 2020
Phase 1
180
erkiudolcf(gknxxxwhyv) = 22.8% of patients treated with eganelisib + nivolumab experienced anemia vyaphjwkpy (vypxmvwqez )
Positive
09 Nov 2020
Phase 1
57
IPI-549 40 mg QD PO + nivolumab 240 mg Q2W IV
xeycrooqal(mcjcnntmad) = njltixrkow ksrwszksyr (qkzywyjfzj )
Positive
01 Dec 2018
Phase 1
82
rixowefniw(trwwhnxeez) = fkennjgqme tasfjcqapv (gehacwakrh )
Positive
10 Nov 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free